欢迎使用我们的服务!
限时优惠,立即购买享受折扣
24小时客服在线,随时为您服务
优质产品,值得信赖
顶 置

BridgeBio’s Infigratinib Poised To Join Achondroplasia Market Early Next Year

BridgeBio’s Infigratinib Poised To Join Achondroplasia Market Early Next Year

The US FDA granted the FGFR3 inhibitor a priority review with an action date in February.